Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.89 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12971103 | 1.00 | ACE2 (0.89) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL12970940 | 1.00 | ACE2 (0.89) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL12970908 | 1.00 | ACE2 (0.89) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL232513 | 1.00 | ACE2 (0.89) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL5879079 | 0.98 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL5879028 | 0.98 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL6294130 | 0.98 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL5879047 | 0.98 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL5878943 | 0.98 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 | |
| SCHEMBL5878803 | 0.98 | ACE2 (0.92) | ACE2BLMGPR84CA1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120053660-A | Hydrophilic complex for preventing, preventing or treating microbial infection, preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120053661-A | Hydrophilic fatty acid complex for preventing, preventing or treating microbial infection, preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119855607-A | Carbon chain substance for regulating transmembrane transport and fluidity of cell membrane, preparation and application | 太阳雨林(北京)生物医药有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4520348-A1 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | Sunforest (Beijing) Biopharma Ltd (CN) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213310-A9 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | 太阳雨林(北京)生物医药有限公司 | 2025-02-20 | — | — | WO | disclosed |
| WO-2023213310-A1 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | 太阳雨林(北京)生物医药有限公司 | 2023-11-09 | — | — | WO | disclosed |
| US-20230142090-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIBRIO INFECTION | CORNELL UNIVERSITY | 2023-05-11 | — | — | US | disclosed |
| EP-4126809-A2 | COMPOSITIONS AND METHODS FOR INHIBITING VIBRIO INFECTION | Cornell University (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115607677-A | Compound for preventing, preventing or treating microbial infection and preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-114569726-B | Compound for preventing, preventing or treating microbial infection and preparation method and application thereof | 太阳雨林(北京)生物医药有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-114788872-A | Compound for preventing, preventing or treating microbial infection and preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114569726-A | Compound for preventing, preventing or treating microbial infection and preparation method and application thereof | 太阳雨林(北京)生物医药有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2021202632-A2 | COMPOSITIONS AND METHODS FOR INHIBITING VIBRIO INFECTION | CORNELL UNIVERSITY (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20200330420-A1 | LONG CHAIN FATTY ACID FORMULATIONS AND THEIR USE IN INHIBITING SALMONELLA INFECTION | CORNELL UNIVERSITY | 2020-10-22 | — | — | US | disclosed |
| EP-2508171-A1 | Pharmaceutical magnetic nano-particle composition | UNIVERSITÄTSKLINIKUM ERLANGEN (DE) | 2012-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142090-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIBRIO INFECTION | FASN, VGF, PLA2G2F | ACE2 703/4885BLM 3584/4885GPR84 2422/4885 |
| US-20200330420-A1 | LONG CHAIN FATTY ACID FORMULATIONS AND THEIR USE IN INHIBITING SALMONELLA INFECTION | FABP2, SLC27A2, SLC10A2 | ACE2 3256/4885BLM 4785/4885GPR84 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.